Table S1. Patients characteristics

		CCS n = 61	ACS n = 29	AoS n = 40	*P-*value
Age, years, mean (SD)		69 (9)	68 (10)	74 (9)	0.009
Sex	Women, n (%)	19 (31.1)	7 (24.1)	17 (42.5)	0.25
	Men, n (%)	42 (68.9)	22 (75.9)	23 (57.5)	
BMI, kg/m^2, median (IQR)		27 (24–30)	28 (26–32)	28 (25–33)	0.19
Hypertension, n (%)		54 (88.5)	24 (82.8)	37 (92.5)	0.46
Hypercholesterolemia, n (%)		55 (90.2)	25 (86.2)	35 (87.5)	0.82
Diabetes, n (%)		33 (54.1)	10 (34.5)	17 (42.5)	0.19
Diabetes on oral drugs, n (%)		26 (42.6)	6 (20.7)	14 (35)	0.14
Diabetes on insulin, n (%)		7 (11.5)	4 (13.8)	3 (7.5)	0.67
Current smoking, n (%)		34 (55.7)	20 (69.0)	12 (30)	0.003
COPD/asthma, n (%)		4 (6.6)	0 (0)	8 (20)	0.013
Creatinine, μmol/l, median (IQR)		83 (72–98)	91 (82–116)	83 (74–110)	0.12
eGFR, ml/min/1.73 m^2, median (IQR)		79 (62–89)	69 (52–82)	73 (49–88)	0.24
TSH, μIU/ml, median (IQR)		1.72 (0.94–3.15)	1.48 (0.80–2.77)	1.56 (0.99–2.35)	0.63
Hyperthyroidism[a], n (%)		2 (3.4)	0 (0)	3 (8.8)	0.35
Hypothyroidism[a], n (%)		12 (20.7)	0 (0)	4 (11.8)	0.026
Prior myocardial infarction, n (%)		21 (34.4)	27 (93.1)	11 (27.5)	<0.001
Prior stroke, n (%)		7 (11.5)	3 (10.3)	4 (10)	1
Atrial fibrillation, n (%)		11 (18.0)	5 (17.2)	16 (40)	0.025

Anticoagulants, n (%)	14 (23.0)	6 (20.7)	16 (40)	0.11
Non–vitamin K oral anticoagulants, n (%)	12 (19.7)	6 (20.7)	14 (45)	0.2
Vitamin K antagonists, n (%)	2 (3.3)	0 (0)	2 (5)	0.69
Antiplatelets, n (%)	54 (88.5)	28 (96.6)	24 (60)	<0.001
Aspirin, n (%)	51 (83.6)	23 (79.3)	21 (52.5)	0.002
P2Y$_{12}$ inhibitors, n (%)	40 (65.6)	24 (82.8)	6 (15)	<0.001

[a]Lack of data for 13 patients

Abbreviations: ACS, acute coronary syndrome; AoS, aortic valve stenosis; BMI, body mass index; CCS, chronic coronary syndrome; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; IQR, interquartile range; TSH, thyroid stimulating hormone